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Response to Drs Pierard and Lauwers 
Clin Microbiol Infect 1998; 4: 415-416 
We should like to thank you for giving us the 
opportunity to respond to the letter from D. Pikrard 
and S. Lauwers concerning the continuing education 
article ‘Enteric infections due to Esckerickia coli’ [ 11. 
First, we should like to make it clear that the aim of our 
paper was to give an overview of E. coli associated with 
enteric infections, with particular emphasis on the 
SLTEC pathotype, which is of growing importance in 
medical microbiology. The purpose was certainly not 
to establish a new nomenclature for this pathotype. In 
addition, our paper was written on the basis of the 
articles published in international journals. 
In our paper no mention was made of the second 
denomination of Shiga-like toxins (SLT): verotoxins or 
verocytotoxins (VT). We agree that this could have 
been done. However, we believe that this denomin- 
ation is not the most suitable, as the term ‘verotoxin’ 
was initially used to designate toxins which were active 
selectively on Vero cells [2]. Since these studies, the 
toxic effects of these proteins have been demonstrated 
on many other cell lines in vitro and in vivo (see 
references in our paper). Therefore, in our view the VT 
denomination is too restrictive. In any case, an 
interested reader, though not familiar with the subject, 
will probably understand that SLT and VT are inter- 
changeable names if he refers to the articles cited in the 
reference section of our paper. We are also surprised by 
the sentence in the letter of Drs Pihard and Lauwers 
concerning the denomination of the Shiga-like toxins, 
in which it is stated that these are ‘now generally 
referred to as Shiga toxins’. No mention of this term 
can be found in the references cited in either their letter 
or our paper. Furthermore, concerning the newly pro- 
posed nomenclature for EHEC, the review by Nataro 
and Kaper [3] was not yet published when we sent our 
paper; thus, no mention could have been made of this 
new definition. In the text, we used the term SLTEC 
for the E. cofi strains producing SLT toxins, irrespective 
of their serotype (0157:H7 or non-O157:H7) or their 
ability to promote attachment/effacement lesions. We 
proposed that ‘SLTEC strains can be classified as EHEC 
when they cause diarrhea or HUS’ (last sentence in 
question 1). Once again, our purpose was not to re- 
define all the terminology on this subject. 
Answer 2a states that ‘non-0157 strains are not 
commonly implicated in cases of SLTEC infections in 
Europe’. We used the term ‘commonly’ and did not 
state that only 0157  isolates are associated with infec- 
tions. This statement is based on two articles published 
in 1996 (references 7 and 8 in our paper) in which it 
was shown that the main cause of HUS in western 
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Europe and in the Czech Republic was 0157  strains. 
Moreover, it was pointed out in our text (citing refer- 
ences 8 and 9) that non-0157 strains could also be 
associated with HUS. We apologize for omitting to cite 
the paper published by Pitrard et a1 [4], in which it was 
possible to read in the results section that ‘cases of HUS 
were only observed in association with serogroup 
0157,  which seems to be more pathogenic than the 
non-0157 strains’ and in the discussion section that ‘by 
using these PCR or immunologic techniques, it will be 
possible to better define the role of non-0157 VTEC 
strains . . . as etiologic agents of diarrhea, hemorrhagic 
colitis and HUS’. It seems from this paper that the 
role of non-0157 strains in infections needs to be 
established. 
Answer 4b states that almost all SLTEC strains 
produce SLT-11. To date, most of the studies performed 
on SLTEC infections have identified 0157  strains in 
outbreaks. Consequently, as almost all 0 1 5 7  strains 
produce SLT-11, we can state that almost all SLTEC 
strains produce SLT-11. Once more, the authors 
referred to a new definition of the EHEC strains 
proposed in the review which was not published when 
we sent in our paper [3].  It  is certain that when all 
SLTEC strains are efficiently detected in stools the 
statistics will be different from those cited in our article. 
As far as question 5c is concerned, since sorbitol- 
producing 0 1  57 strains have been isolated in Europe, 
though in a restricted area, we do think that it is 
important to keep in mind that the SMAC selection is 
now 100% reliable for all SLTEC isolates. We agree 
that, a t  present, other techniques are not easy to use in 
routine laboratories. However, these must be developed 
in the future, since they are more reliable. 
In the answer to question 6e, we said that antibiotic 
therapy is possible because ‘most E.  coli 0157:H7 are 
susceptible to a broad range of antibiotics’. However, 
we also indicated that the use of antibiotics is contro- 
versial and that at  present no clear answer can be given 
to the readers. As suggested by Pitrard and Lauwers and 
as stated in our paper, ‘authorities recommend that 
infected children should not return to group settings 
until at  least two negative stool cultures have been 
obtained’. 
In conclusion, as will be understood even by a 
reader unfamiliar with the subject, this field of research 
is quite new and remains very controversial. More data 
must be obtained before it can be established whether 
strains irolated in Europe and the USA are clearly of 
different origins. It is also true that diagnosis of SLTEC 
infections needs to be improved and that a common 
nomenclature will have to be used. However, we feel 
strongly that a continuing education paper is not the 
most appropriate place for exploring these issues. 
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